Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, both Unani formulations tested were effective in managing Telogen Effluvium, with Itrifal Kishneezi and Roghan Amla showing slightly faster early results in reducing hair shedding, although overall efficacy between the two treatments was comparable.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

In this study, both finasteride and hydroxychloroquine were found to be equally effective, safe, and well-tolerated first-line treatments for frontal fibrosing alopecia in female patients, with no significant differences in efficacy between the two therapies over six months.

In this study on male androgenetic alopecia, the researchers reported significant increases in hair count, density, and thickness with minimal side effects over 6 weeks using adipose-derived stem cell conditioned media and minoxidil, but found no significant differences between concentrated and non-concentrated treatments.

This study found that platelet-rich plasma was effective for hair regrowth in women with androgenic alopecia, though less so than minoxidil, but it was associated with improved quality of life responses.

In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

This study found that 1mg/day oral finasteride significantly improved androgenetic alopecia in Chinese men, with a higher efficacy rate compared to placebo and minimal adverse effects.

This study found that 2.2% minoxidil gel was more effective than placebo in treating alopecia areata and reported similar safety outcomes between the two groups.

Platelet-rich plasma helps hair regrowth and improves quality of life in women with hair loss, but minoxidil may be more effective.

This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study concluded that fenugreek improved lipid profiles in women with PCOS compared to metformin, but cannot substitute metformin for PCOS treatment; it may serve as an adjuvant therapy for those with hyperlipidemia.

This systematic review examined 64 randomized controlled clinical trials on regenerative medicine for specific dermatologic disorders, reporting up to 68.4% improvement in androgenetic alopecia and up to 71% improvement in vitiligo among 2888 patients.

This study found that free testosterone levels were 29% higher with the levonorgestrel implant than with the DMPA injection, which may impact sexual function, mood, and side effects like acne.

This trial explores whether spironolactone is more effective than cyclines for treating moderate acne in adult women, providing a potential alternative amidst concerns over antibiotic resistance.

This review examines the use and efficacy of Panax ginseng in various clinical settings, noting that clinical trial outcomes vary widely based on study conditions and ginseng types; no new results are reported.

This study found that combining bromhexine and spironolactone was effective in improving clinical outcomes and reducing viral load or hospitalization duration in patients with mild to moderate COVID-19.

This study reported that using 5% minoxidil topical foam twice daily improved hair density and width in both the frontotemporal and vertex regions of men with moderate androgenetic alopecia.

This abstract does not provide specific results or a conclusion; additional context is needed to interpret the data.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

In this pilot study on treating dorsal wrist ganglion, PRP injection showed limited effectiveness at 1-year follow-up compared to aspiration alone, with most PRP-treated patients experiencing ganglion recurrence, suggesting that an RCT would need at least 46 patients per group to further assess PRP's utility.

In this study, both 5% minoxidil foam and 5% minoxidil liquid solution effectively improved hair diameter and density in male patients with androgenetic alopecia over 12 weeks, with the foam formulation showing a slight advantage in patient satisfaction and hair density gain.

The hypothesis in this study is that probiotic supplementation could improve hormonal, metabolic, inflammatory, and antioxidant markers in individuals with PCOS compared to a placebo, although results are not yet reported.

This systematic review found that probiotic supplementation improved sleep quality, reduced depressive symptoms, and enhanced aspects of quality of life in women with PCOS, though the findings are limited by a small number of studies and variable methods.

This study describes a planned multicenter randomized controlled trial to assess the safety, tolerability, and pharmacokinetics of subdermal gestrinone pellets in patients with deep infiltrative endometriosis-related pelvic pain, but it does not report any findings yet.

This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.

This systematic review found that both cellular and acellular stem cell-based therapies are safe and able to improve hair regeneration and density in patients with androgenic alopecia, although some results may be temporary.